Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades8
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron shares surge on FDA drug designation; loss widens on costs
29 Aug 2023 - UK earnings, trading statements calendar - next 7 days
22 Aug 2023 - Faron Pharmaceuticals sees positive data from phase 1 BEXMAB trial
19 Jul 2023 - TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend
29 Jun 2023 - TRADING UPDATES: Medica shareholders back takeover; Arecor optimistic
9 Jun 2023 - Faron Pharmaceuticals test data shows efficacy of bexmarilimab
24 Apr 2023 - TRADING UPDATES: Anglo Asian gold output down; Faron hails antibody
17 Apr 2023 - Faron Pharma names James O'Brien, once of Bristol-Myers, as new CFO
29 Mar 2023
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron shares surge on FDA drug designation; loss widens on costs
(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its interim loss widened on higher costs but saw shares soar after it gained a US Food & D...
Faron Pharmaceuticals sees positive data from phase 1 BEXMAB trial
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said data from its phase 1 BEXMAB study has shown positive data.
TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:
TRADING UPDATES: Medica shareholders back takeover; Arecor optimistic
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Friday and not separately reported by Alliance News:
Faron Pharmaceuticals test data shows efficacy of bexmarilimab
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said further data from its Phase I/II MATINS study of bexmarilimab has indicated the efficacy an...
TRADING UPDATES: Anglo Asian gold output down; Faron hails antibody
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Faron Pharma names James O'Brien, once of Bristol-Myers, as new CFO
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said it has appointed James O'Brien as its new chief financial officer, effective from Monday...
Follow the stocks
